【诺和诺德收购Catalent交易已获准完成】 诺和诺德当地时间12月14日宣布，与诺和控股收购美国合同制药商Catalent的审查相关的所有监管成交条件均已满足，双方现在可以自由完成交易。诺和诺德预计收购将在未来几天内完成。

诺和诺德 当地时间12月14日宣布，与诺和控股收购美国合同制药商Catalent的审查相关的所有监管成交条件均已满足，双方现在可以自由完成交易。诺和诺德预计收购将在未来几天内完成。

Johnson & Johnson sues Cigna divisions, McKinsey resolves opioid charges, and numerous FDA approvals affect companies like ...

Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their ...

当地时间12月14日，诺和诺德宣布，其大股东诺和控股以165亿美元收购美国合同制药商康泰伦特（Catalent）相关的所有监管交割条件均已满足，双方现在可自由完成交易，以及诺和诺德随后从诺和控股收购三个康泰伦特制造基地。诺和诺德预计收购将在未来几天完成。

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the ...

Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...

Danish pharma giant Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, is set to boost production with a ...

(Bloomberg) -- Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing ...